Neurologia
Diretriz | Tratamento fisioterápico da doença de Parkinson.
28 Jan, 2022 | 16:57hUm estudo de caso-controle de amplitude nacional e de base populacional mostrou que visitas ao dentista não foram associadas com risco aumentado de abscesso cerebral.
28 Jan, 2022 | 16:36hDentist’s visits and risk of brain abscess: a nationwide, population-based case control study – Clinical Infectious Diseases (link para o resumo – $ para o texto completo)
Comentário no Twitter
Finally💥
High-quality large-scale clinical study on brain abscess
Dentist’s visits & risk of brain abscess
Recent invasive dental procedures & number of dentist’s visits were NOT associated w culture verified brain abscess caused by oral cavity bacteria https://t.co/ziEke7eBYm— Antibiotic Stewa®️x🆔 Bassam Ghanem (@ABsteward) December 30, 2021
Estudo de coorte | Entre sobreviventes de tratamento em UTI para COVID-19, 75% ainda relatam sintomas físicos, mentais e cognitivos depois de 1 ano.
28 Jan, 2022 | 15:45hComentários:
75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP
Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical
Revisão | Diagnóstico e tratamento do distúrbio neurológico funcional.
25 Jan, 2022 | 14:49hDiagnosis and management of functional neurological disorder – The BMJ
Estudo randomizado | Segurança e eficácia do daridorexante em pacientes com distúrbios de insônia.
25 Jan, 2022 | 14:43hSafety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials – The Lancet Neurology (link para o resumo – $ para o texto completo)
Perspectiva | Consequências da COVID-19 para o sistema nervoso.
21 Jan, 2022 | 15:57hNervous system consequences of COVID-19 – Science
Conteúdos relacionados:
Review: Counting the neurological cost of COVID-19.
Neurological Effects of COVID-19 in Children.
International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.
Short review: Neurological complications of COVID-19.
2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.
M-A: Encephalitis as Neurological Complication of COVID‐19.
Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditionsEight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).
Comentário no Twitter
A new #SciencePerspective discusses the neurological symptoms that accompany #COVID19 and the possible mechanisms that cause them. Read more: https://t.co/WKZpnWlbNc pic.twitter.com/U4ohecaVQd
— Science Magazine (@ScienceMagazine) January 20, 2022
Revisão sistemática | Em pacientes com doença de Alzheimer e demência vascular com agitação e psicose, antipsicóticos atípicos provavelmente reduzem um pouco a agitação (certeza moderada de evidência), mas podem ter efeito negligenciável sobre a psicose ou o risco de qualquer evento adverso.
21 Jan, 2022 | 15:45hVisão geral atualizada do tratamento da dor lombar.
21 Jan, 2022 | 15:25hAn Updated Overview of Low Back Pain Management – Asian Spine Journal
Revisão | Medicamentos à base de Cannabis e cannabis de uso medicinal para dor neuropática crônica.
20 Jan, 2022 | 22:38hCannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain – CNS Drugs
Conteúdos relacionados:
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.
Cannabis products are being sold as sleep remedies – here’s the evidence about their effectiveness.
Guideline: Medical cannabis or cannabinoids for chronic pain.
NICE Guideline: Cannabis-Based Medicinal Products
Short Review: Drug Interactions with Cannabinoids
Meta-Analysis: Cannabinoids Not Effective for Cancer-Related Pain
Estudo randomizado | Segurança e eficácia do oxibato de baixo sódio em adultos com hipersonia idiopática.
20 Jan, 2022 | 21:39hSafety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study – The Lancet Neurology (link para o resumo – $ para o texto completo)


